title: [Triple cutaneous mycosis (Cunninghamella bertholletiae, Phomopsis spp. and Paraconiothyrium spp.) in an immonucompromised patient: a Martinican case report].
abstract: BACKGROUND
  Patients from hematology department, with a weak immune system, can develop opportunist infections due to environment moulds that proliferate without notion of accidental inoculation or pre-existent lesion.
  
  
  METHODS
  We report a triple cutaneous infection case caused by Cunninghamella bertholletiae, Phomopsis spp. and Paraconiothyrium spp. on three different anatomic sites in a 68-years-old Martinican patient treated with high-dose chemotherapy and long-term corticotherapy for B-cell lymphoma and who also developed necrotic placards of legs. The patient's condition improved after stopping corticotherapy, treatment by voriconazole and medullary restoration.
  
  
  CONCLUSIONS
  We will discuss about cases described in literature about those rare and different kinds of pathogenic agents while considering evolution, topography of lesions in our case, in order to focus on specificities. We shall emphasize the necessity to be careful about cutaneous hurt in immunocompromised patients.
authors.affiliation: Service de dermatologie, CHU de Fort-de-France, hôpital Pierre-Zobda-Quitman, BP 632, 97261 Fort-de-France, Martinique.
authors.forename: C
authors.initials: C
authors.lastname: Quillet-Dye
authors.forename: J-C
authors.initials: JC
authors.lastname: Meniane
authors.forename: D
authors.initials: D
authors.lastname: Quist
authors.forename: N
authors.initials: N
authors.lastname: Desbois
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D060085:Coinfection; D020093:Cunninghamella / Q000302:isolation & purification*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003881:Dermatomycoses / Q000150:complications / Q000382:microbiology*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D016867:Immunocompromised Host; D008224:Lymphoma, Follicular / Q000150:complications / Q000188:drug therapy; D008297:Male; D008395:Martinique; D009091:Mucormycosis / Q000150:complications / Q000382:microbiology*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D000069283:Rituximab; D004718:Saccharomycetales / Q000302:isolation & purification*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000305:Adrenal Cortex Hormones; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone